InsiderSignal.AI

InsiderSignal.ai

NMRA - Neumora Therapeutics, Inc.

Insider Purchase by Burow Kristina (Dir, 10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

3 months ago, Burow Kristina, serving as Dir, 10% owner at Neumora Therapeutics, Inc. (NMRA), purchased 1,915,700 shares at $2.61 per share, for a total transaction value of $4,999,977.00. Following this transaction, Burow Kristina now holds 33,895,555 shares of NMRA.

This purchase represents a 6.00% increase in Burow Kristina's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, October 27, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, October 29, 2025, 2 days after the trade was made.

Neumora Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Burow Kristina

Dir, 10%

Kristina Burow is an independent Class I director at Neumora Therapeutics, Inc. (NMRA), serving since January 2020 with her current term expiring at the 2027 annual meeting.[[1]](https://fintool.com/app/research/companies/NMRA/people/kristina-burow) She chairs the Compensation Committee and serves on the Nominating & Corporate Governance Committee, previously on the Audit Committee until April 2025, and maintains strong attendance records.[[1]](https://fintool.com/app/research/companies/NMRA/people/kristina-burow) As a Managing Director at ARCH Venture Partners since November 2011 (joining in 2002), she focuses on creating and developing biotechnology, pharmaceutical, and health tech companies, co-founding successes like Receptos (acquired by Celgene) and Orbital Therapeutics.[[1]](https://fintool.com/app/research/companies/NMRA/people/kristina-burow)[[2]](https://neumoratx.com/our-team/kristina-burow/)[[3]](https://www.vcsheet.com/who/kristina-burow) Burow's career highlights include prior roles at Novartis BioVenture Fund and as an early employee at the Genomics Institute of the Novartis Research Foundation, directing chemistry operations and business development.[[1]](https://fintool.com/app/research/companies/NMRA/people/kristina-burow)[[2]](https://neumoratx.com/our-team/kristina-burow/) She serves on multiple public and private biotech boards, including Beam Therapeutics, Scholar Rock, Boundless Bio, and Autobahn Therapeutics, with experience across gene editing, CNS, and other modalities.[[1]](https://fintool.com/app/research/companies/NMRA/people/kristina-burow)[[2]](https://neumoratx.com/our-team/kristina-burow/)[[3]](https://www.vcsheet.com/who/kristina-burow) Education: B.S. in Chemistry (UC Berkeley), M.A. in Chemistry (Columbia University), M.B.A. (University of Chicago Booth).[[1]](https://fintool.com/app/research/companies/NMRA/people/kristina-burow)

View full insider profile →

Trade Price

$2.61

Quantity

1,915,700

Total Value

$4,999,977.00

Shares Owned

33,895,555

Trade Date

Monday, October 27, 2025

118 days ago

SEC Filing Date

Wednesday, October 29, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Neumora Therapeutics, Inc.

Company Overview

No company information available
View news mentioning NMRA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/979220

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime